Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery

• Status: Unknown status
• Trial end date: 2017-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Use of dexmedetomidine in pituitary tumor resection surgery as adjuvant drug and its relation to cortisol levels during postoperative period.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pontificia Universidad Catolica de Chile
• Treatments: Cortisol succinate; Dexmedetomidine; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate

Criteria

Inclusion Criteria:

• American Society of Anesthesiologists physical status I or II.

• Pituitary tumour: non-functional macroadenoma, Rathke's cleft cyst, acromegaly.

• Normal hypothalamic-pituitary-adrenal axis by hormone levels measurement previous to surgery.

Exclusion Criteria:

• Cushing disease.

• Pituitary apoplexy.

• Craniopharyngioma.

• Chronic corticosteroid use.

• Hemodynamic instability.

• Altered consciousness (Glasgow Coma Scale score less than 15).

• Atrioventricular block in any degree.

• Preoperative bradycardia.

• Alpha 2 agonist use (clonidine, alpha-methyldopa)

• Pregnancy or breast feeding.

• Known allergy to any of the study drugs.